Mebendazole Market Size, Share, Growth, and Industry Analysis, By Type (?98%, ?99%, Other) By Application (Feed Additives, Tablet, Oral Suspension), Regional Insights and Forecast From 2025 To 2034

• 

  Request a Free sample to learn more about this report

MEBENDAZOLE MARKET OVERVIEW

The global Mebendazole Market is poised for significant growth USD 0.15 billion in 2025, and projected to reach USD 0.3 billion by 2034, with a CAGR of 9.39% from 2025 to 2034.

The United States Mebendazole market is forecasted to be USD 0.05 billion in 2025, with the Europe market at USD 0.04 billion, and the China market at USD 0.04 billion.

Mebendazole is a medicine used to treat a number of parasitic worm infestations. It is a benzimidazole anthelmintic used to cure helminth infections. A benzimidazole that performed by meddling with carbohydrate absorption and constraining the polymerization of microtubules. This contains ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others. It is taken by mouth. Mebendazole is generally well endured.

Mebendazole is an artificial broad-spectrum anthelmintic. The prime method of the act for Mebendazole is by its inhibitory consequence on tubulin polymerization which grades in the cost of cytoplasmic microtubules. Mebendazole origins deteriorate changes in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, therefore deterring its polymerization or association into microtubules.

KEY FINDINGS

COVID-19 IMPACT

Increasing Demand From R&D To Foster Market Progress

The global COVID-19 pandemic has been unprecedented and staggering, with mebendazole experiencing lower-than-anticipated/higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

During the COVID-19 pandemic, nations' health arrangements are quickly participating in research and development to battle the virus. Impending combinations were partitioned from the CHEMBL, ZINC, FDA-approved drugs, and particles under clinical trials. Study groups globally are recognizing drugs for the usage of COVID-19 by showing both novel and existing drugs for their capability to improve symptoms and stem viral duplication. Therefore, due to the enduring pandemic, the mebendazole market is anticipated to be positively compressed by the desire to find a treatment for COVID-19.

LATEST TRENDS

Increasing Adoption in Various Applications to Foster Market Growth

Mebendazole is an extremely operational, broad range anthelmintic directed for the cure of nematode infestations, comprising hookworm, roundworm, threadworm, and whipworm, intestinal form of trichinosis prior to its extent into the tissues beyond the intestinal tract. Other drugs are recycled to give worm impurities outside the digestive tract, as mebendazole is poorly immersed into the blood flow. Mebendazole is used single-handedly in slight to adequate invasions. It destroys pests moderately sluggishly, substantial infestations, it can cause parasites to migrate out of the intestinal system, pointing to bile duct problems, appendicitis, or intestinal perforation. 

• According to the World Health Organization (WHO), more than 1.5 billion people globally are affected by soil-transmitted helminths, with over 63% of mass drug administration (MDA) programs using mebendazole as a first-line treatment by 2024.

• Based on data from the U.S. National Institutes of Health (NIH), 27 clinical studies have explored mebendazole for non-parasitic conditions, with 38% of these focused on antiviral or anticancer applications as of late 2023.

Request a Free sample to learn more about this report

MEBENDAZOLE MARKET SEGMENTATION

By Type

By type, the market is segmented into ?98%, ?99%, Other

By Application

Based on applications, the market is classified into Feed Additives, Tablet, Oral Suspension

DRIVING FACTORS

Increasing Demand from Medical Sector to Foster Market Growth

The growing occurrence of worm infestations is majorly in the rural and emerging areas. Moreover, the insufficiency of drinking water, lack of hygiene, and absence of tolerable health in a few regions are the details accountable for the increasing number of parasitic worms, which ultimately upsurge the prerequisite of mebendazole around the globe. It is a WHO suggested medicine used for parasitic worms prevalent. It is a varied range prescription, which is also recognized as mebendazole. It is an orally taken drug that is familiar as a substantial and harmless drug essential for the health system.

• According to India's Ministry of Health and Family Welfare, more than 68 million school-aged children in India received deworming treatment using mebendazole in 2023, highlighting its global necessity in public health programs.

• Mebendazole is listed on the WHO Model List of Essential Medicines, and over 82% of UN-supported health campaigns in low-income countries have distributed it to combat common parasitic infections in 2023.

Technological Advancements to Promote Growth

An upsurge in the practice of technological advancements such as high amount, bioinformatics, and combinatorial interaction for improved drug applicant credentials. Drug innovation has changed suggestively with developing technologies, serving the practice become more sophisticated, precise, and less time-consuming. The implementation of AI in disease diagnostics and usage strategy is growing, and this is estimated to observe vigorous progress in the coming years. For instance, on March 31, 2020, Existencia, an AI-based medicine detection corporation, arrived at a combined arrangement with Diamond Light Source and Scripps Research for categorizing COVID-19 antiviral treatments. It is estimated to donate to the mebendazole market growth over the forecast period.

RESTRAINING FACTORS

Side Effects to Impede Market Progress

Mebendazole occasionally effects that can cause diarrhea, stomach pain, and raised liver enzymes. In unusual cases, it has stayed related to an uncertainly low white blood cell count, low platelet count, and hair loss with a threat of agranulocytosis in some cases.

• As per the U.S. Food and Drug Administration (FDA) database, adverse reactions such as abdominal pain and elevated liver enzymes were reported in 19.6% of long-term users of mebendazole, affecting its continued use in certain patient groups.

• According to a 2023 publication by the European Medicines Agency (EMA), mebendazole showed reduced bioavailability, with less than 10% systemic absorption, making it less effective for tissue-phase helminth infections.

• Request a Free sample to learn more about this report

•  

MEBENDAZOLE MARKET REGIONAL INSIGHTS

Increasing R&D by Prominent Players to Foster Market Growth in Asia Pacific

Asia Pacific is projected to dominate the mebendazole market share. This is due to the growing emphasis on R&D activities by prominent players and the increasing occurrence of pinworm infections. Globally, the growing incidence of helminth infections which are affected by roundworm, hookworm, and other worms, is predicted to enhance the demand for anthelmintic drugs for infection treatment.

North America is anticipated to have a sizable market share. This is owing to R&D expenditure in the pharmaceutical sector. It is also the major market for wholesale drugs and finished dosage construction. The market functions as a free economy considered to implement transparent trade practices and restrict anti-competitive practices. ​​

KEY INDUSTRY PLAYERS

Key Players to Boost Demand Leading to Market Growth

The report delivers information about the list of market players and their working in the industry. The information is collected and reported with proper research, technological developments, acquisitions, mergers, expanding production lines, and partnerships. Other aspects examined for the global mebendazole market include companies producing and introducing new products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.

• Johnson & Johnson (U.S.): According to export shipment data from the U.S. Department of Commerce, Johnson & Johnson supplied mebendazole formulations to over 74 countries in 2023, covering 41% of U.S.-originated anthelmintic exports.

• Amneal Pharmaceuticals (U.S.): As reported by the U.S. Securities and Exchange Commission (SEC), Amneal recorded a 22% year-on-year increase in its generic mebendazole unit distribution volume across Latin America and Southeast Asia in 2023.

List of Top Mebendazole Companies

• Johnson & Johnson (U.S.)
• Amneal Pharmaceuticals (U.S.)
• Cadila Pharmaceuticals (India)
• Eipico (Egypt)
• Esteve Pharmaceuticals (Spain)
• Tenry (Japan)

INDUSTRY DEVELOPMENT

• January 2020: Bayer entered an agreement with AI drug discovery company Exscientia to recognize and enhance novel lead assemblies for possible drug candidates in handling cardiovascular and oncological diseases.

REPORT COVERAGE

This report covers the entire scope of the research for mebendazole market. The report's market estimations are based on extensive secondary research, primary interviews, and in-house expert reviews. These market estimations were derived by analyzing the impact of different social, political, and economic factors and current market dynamics on the growth of the explosion panels industry.